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Abstract
Background: Cardiovascular disease (including coronary heart disease and stroke) is a major
cause of death and disability in the United Kingdom, and is to a large extent preventable, by lifestyle
modification and drug therapy. The recent standardisation of electronic codes for cardiovascular
risk variables through the United Kingdom's new General Practice contract provides an
opportunity for the application of risk algorithms to identify high risk individuals. This randomised
controlled trial will test the benefits of an automated system of alert messages and practice
searches to identify those at highest risk of cardiovascular disease in primary care databases.
Design: Patients over 50 years old in practice databases will be randomised to the intervention
group that will receive the alert messages and searches, and a control group who will continue to
receive usual care. In addition to those at high estimated risk, potentially high risk patients will be
identified who have insufficient data to allow a risk estimate to be made. Further groups identified
will be those with possible undiagnosed diabetes, based either on elevated past recorded blood
glucose measurements, or an absence of recent blood glucose measurement in those with
established cardiovascular disease.
Outcome measures: The intervention will be applied for two years, and outcome data will be
collected for a further year. The primary outcome measure will be the annual rate of cardiovascular
events in the intervention and control arms of the study. Secondary measures include the
proportion of patients at high estimated cardiovascular risk, the proportion of patients with missing
data for a risk estimate, and the proportion with undefined diabetes status at the end of the trial.
Background
Primary research question
Can an automated system of electronic feedback (e-
Nudge) reduce the incidence of cardiovascular events in
high risk patients in general practice, compared to "usual
care"?
Background
A major focus of chronic disease management is the pre-
vention of cardiovascular disease (CVD). An important
development occurred in UK primary care in April 2004,
with the introduction of the "new General Medical Serv-
ices Contract" (nGMS) [1]. This involved the establish-
ment of registers for a number of conditions relevant to
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tronic record keeping has made the data potentially useful
for research [2]. The Quality and Outcomes Framework
(QOF) of the nGMS specifies targets for blood pressure,
serum cholesterol levels, and smoking cessation advice for
patients with hypertension, diabetes, or established CVD.
Whilst not included in the QOF, the Coronary Heart Dis-
ease (CHD) National Service Framework (NSF) [3] also
recommends the systematic identification of patients at
high risk of CHD but who are not yet displaying any
symptoms.
For many patients, the need for preventive treatment is
clear, for example through a diagnosis of CVD or diabetes,
but for others, the overall cardiovascular risk should be
taken into account when determining the need for treat-
ment of hypertension or hypercholesterolaemia. This
strategy is strongly supported by the recently published
Joint British Societies guidelines on prevention of CVD in
clinical practice [4]. This project will assess the effective-
ness of targeting patients who are the most likely to bene-
fit from risk factor modification on the basis of their
absolute risk of cardiovascular events.
Changing clinical behaviour through electronic reminders
Despite increasing use of electronic reminders and alert
messages, there are relatively few controlled trials that
demonstrate their ability to modify clinical behaviour,
and none so far carried out in the UK under the new Gen-
eral Practice contract. Published literature is largely con-
cerned with the following uses of these tools:
• to increase physician or nurse adherence to guidelines
on best practice in the clinical environment [5], including
the use of drug therapy [6]
• to increase the uptake of vaccinations [7-11]
• to promote other preventive health care activities, by
triggering opportunistic interventions including screening
[12], monitoring [13,14], diagnostic tests [15], and life-
style counselling [16,17]
• to increase the cost-effectiveness of health care, by avoid-
ing duplication, facilitating communication between
members of the health care team [18], and reducing the
need for recall of patients through increased use of oppor-
tunistic activities during consultations
Of these, the most successful area is vaccination uptake,
where a number of studies have demonstrated benefit [7-
10], and in the avoidance of prescribing errors, where
alerts have been shown to be effective in decreasing the
ordering and administration of contraindicated drugs, for
instance due to renal insufficiency [19].
Results in other areas have been mixed [20], and may
depend on the response of the clinician to the alert mes-
sage, which must therefore be appropriately designed
[21]. In a United States outpatient clinic setting, Tierney et
al [22] tested the effects of a system of electronic 'sugges-
tions' for cardiac care patients through a randomised con-
trolled trial, and failed to demonstrate any control-
intervention differences in quality of life, medication
compliance, health care utilisation, costs, or satisfaction
with care. The intervention had no effect on physicians'
adherence to the care suggestions. However in Italy, elec-
tronic reminders have been shown to be effective in mod-
ifying prescribing behaviour. Filippi et al [23] investigated
the effects of computerised reminders plus a letter describ-
ing the beneficial effects of anti-platelet therapy (interven-
tion group) with the letter alone (controls) among 300
Italian general practitioners randomised to each group.
The number of treated patients was significantly raised in
the patients of the intervention group (OR 1.99, 95% CI
1.79 – 2.22).
In Scotland, the CARDIA (Computerised Automated Risk
Detection Intervention and Advice) program [24] serves
practices throughout Angus using a similar system of data-
base integration as that proposed in this e-Nudge study.
CARDIA interrogates the electronic health record (EHR),
which uses information from both primary and secondary
care sources. CARDIA targets resources by examining the
practices' EHRs, identifying patients with existing cardio-
vascular disease (or those at high risk of it based on a
Framingham calculation), and assesses the adequacy of
care (e.g. drug therapy) in individual patients. However
the effectiveness of this program has not been formally
tested in a clinical trial.
In secondary care, Lilford et al [25] have described (but
not evaluated) a system of electronic reminders for use in
the antenatal clinic. This system supplies action sugges-
tions during the antenatal booking interview, as a comple-
ment to individual clinical judgement. Eighty-two
different suggestions were included in the software, and
on average 1.5 of these were generated in an individual
history. The authors emphasise the potential for such sys-
tems to be adapted to the resources and preferences of dif-
ferent hospitals.
Controlled studies similar to the e-Nudge trial
One randomised controlled trial in primary care [26] has
assessed the effectiveness of electronic feedback using off-
line data analysis followed by a flag in the electronic
health record. Randomisation was at the health profes-
sional level. The outcome was the proportion of patients
under the care of each professional still eligible for an alert
a month later. This design is in some ways similar to this
e-Nudge trial, and the result was positive, but it took placePage 2 of 13
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with follow-up one month later. In secondary care, the
effectiveness of a similar intervention aimed at clinicians
caring for hospital inpatients at risk of deep vein throm-
bosis (DVT) was more dramatically demonstrated [27]. In
this case randomisation was at the individual patient level
and the outcome was the actual development of DVT. The
intervention group patients were found to have a 40%
reduced rate of thrombosis compared with controls. A
similarly-designed study of electronic reminders for the
improved care of patients with HIV infection achieved a
significant reduction in hospitalisation in the interven-
tion group [28].
Mitchell et al [29] used information extracted from Scot-
tish general practices to target care towards those aged 65–
79 years most in need of intervention for their blood pres-
sure. Information was extracted annually, and 54 practices
were cluster-randomised into three groups: those receiv-
ing feedback of information identifying patients with
uncontrolled blood pressure, those receiving the same
feedback but including patients' estimated absolute cardi-
ovascular risk, and control practices receiving no feed-
back. Whilst reductions in the proportion of patients with
controlled blood pressure were seen, the results were com-
promised by difficulties in stratification according to prac-
tice characteristics (resulting in an excess of controls that
were training practices, and having a hypertension recall
system).
Evidence published to date suggests that the benefits of
electronic reminders are context-dependent, relying not
only on the area of care involved, but also on organisa-
tional parameters, clinical targets, and medicolegal impli-
cations. A Veterans Health Administration study [30]
demonstrated significant variation in the implementation
of electronic reminders including their greater use for con-
ditions associated with performance measures. Agarwal et
al [31], in a study of 15 different computerised reminders
found that while overall adherence was high, there is sig-
nificant variation by clinic, individual clinician and indi-
vidual reminder. For instance, the hepatitis C risk
assessment reminder was found to have the highest over-
all adherence rate (95.9%) and the tobacco use cessation
had the lowest adherence rate (62.9%). Dickey et al [32]
have reviewed the literature on a range of office based
tools for improving behavioural change counselling in
primary care. This included all types of tool, including
electronic reminders. They found that no one type of tool
or method of teamwork was consistently more effective
than another, and identified the need for more high qual-
ity research, particularly in the area of health risk assess-
ment and electronic reminder systems.
There is therefore mixed evidence supporting the effective-
ness of electronic reminders and a need to confirm their
ability to modify clinical behaviour in the particular con-
text of UK primary care under the new GMS Contract.
Overview of study design
This is a randomised controlled trial to test the effect of an
automated electronic feedback system on CVD prevention
in general practice. The practice populations over the age
of 50 years will be randomised into two groups: "interven-
tion" and "control". Intervention patients currently
belonging to one of the high risk search groups described
below will have alert messages appear on the screen when
their electronic notes are opened. We will also apply an
electronic search protocol every eight weeks to both
groups throughout the study, to produce continually
updated lists of potentially high risk patients for cardio-
vascular events. For the intervention group the patients on
these lists will be revealed to the practice. The clinical soft-
ware company EMIS, who serve the majority of practices
in Warwickshire and Coventry, have programmed their
software to produce the alerts and the eight-weekly lists
for intervention patients. This "intervention" involves the
feedback to practice teams to identify patients who are
currently at high estimated risk, patients whose data is
incomplete (who may benefit from updated measure-
ments of cholesterol, blood glucose, blood pressure or
recording of smoking status) and those who may have
undiagnosed diabetes, through the alert messages and the
eight-weekly lists. The control group will receive the usual
care provided under the nGMS contract. No information
will be withheld from the clinicians regarding control
patients, the only difference will be the absence of
reminders to draw their attention to the information. The
practice teams themselves will decide on any changes in
treatment in consultation with individual patients in both
arms of the study, allowing care to remain tailored at the
clinician-patient level. Outcomes will include the number
of cardiovascular events and the number of high risk
patients in the two populations (defined by inclusion on
the eight-weekly search results). The design of the search
protocol and the justification for the thresholds are
described in the appendix.
Methods
Recruitment
Up to twenty-six general practices in Coventry and War-
wickshire who use EMIS LV software will be invited to par-
ticipate in the trial. Dr Tim Holt will visit each practice to
explain the trial and gain written consent from the general
practitioners.
Randomisation
Participating practice patients over 50 years of age will be
randomised into two groups – "intervention" and "con-Page 3 of 13
(page number not for citation purposes)
Trials 2006, 7:11 http://www.trialsjournal.com/content/7/1/11trol." Patients will be consistently allocated to these
groups throughout the study using an electronic tech-
nique that is concealed to all researchers and practitioners
involved. This process will occur electronically during
each search, so that those who join the practice during the
study will be randomised automatically as soon as they
are first provided with electronic notes as a fully registered
patient. Temporary residents are not included in the
study.
Applying the search strategy
Alerts will be created automatically using patient informa-
tion that is updated in real time and the search protocol
described in Figures 1, 2, 3. For the eight-weekly lists we
will apply the same search protocol to the databases of
participating practices. This will produce lists for each
practice of the high modifiable risk patients in the inter-
vention arm of the study on the day of the search. The
groups identified can be summarised as:
GROUP 1: Patients of all ages with existing cardiovascular
disease or diabetes, whose blood pressure or cholesterol
level is outside the QOF target range at the last estimation,
or no "in date" level is recorded.
GROUP 2: Patients who are not known to have cardiovas-
cular disease or diabetes, are under 75 yrs old, and whose
risk profile is incomplete – more information is required
to perform a risk estimate – but whose cardiovascular risk
would be greater than 20% if the "assumed" values of the
missing factors are used (see definition in appendix).
GROUP 3: Patients who are not known to have cardiovas-
cular disease or diabetes, are under 75 yrs old, and whose
most recent risk variable values indicate that their risk
level is raised.
GROUP 4: Patients who are not known to have cardiovas-
cular disease or diabetes, are greater than 75 yrs old and
who have persistently elevated blood pressure based on
the three most recent consecutive readings.
GROUP 5: Patients with possible undiagnosed diabetes
on the basis of at least one previous high blood glucose
record.
GROUP 6: Patients with CVD but not diabetes, who have
not had a blood glucose measurement in the past three
years.
Information on the "intervention" patients identified at
each search is revealed to the practices. Information on
the control patients including the number identified will
be saved but no action will be triggered (Figure 4).
Intervention – the "e-Nudge"
The e-Nudge is an automated feedback system that exam-
ines information already contained in practice databases
to help practice teams target preventive interventions
towards the individuals most likely to benefit. At the same
time, the e-Nudge identifies clinically important missing
risk variable values and patients with possible undiag-
nosed diabetes. Designed to run as a series of updated
alert messages and searches that use most recent risk vari-
able values, it is able to track practice populations over
time as patients enter and leave the area, grow older, and
enter practice disease registers, such as those for diabetes,
CHD, or stroke. It recognises that risk profiles are
dynamic, and that "one-off" estimates of risk in individu-
als are liable to become outdated [33].
The alert messages will arise automatically through EMIS
software when a high risk patient's notes are opened, and
are continuously updated in real time. To identify patients
who may not present to the practice, electronic searches
will be undertaken every eight weeks. The purpose of both
alerts and the lists is to trigger awareness of individual
patients' risk within the practice team, and not to dictate
specific treatments. The "e-Nudge" is therefore simply the
feedback of this information. The resulting action is at the
discretion of the practice team, and can be tailored both
to the time available, and to the needs and preferences of
the individual patient in the context of the clinician's
broader knowledge of co-morbidity, current medication,
and past response to treatment. The practice teams will
have the following notifications for intervention patients
identified in the searches.
1 The eight-weekly search result is presented to a nom-
inated member of the primary care team under the six
group headings.
2 Alert messages are displayed automatically on the com-
puter screen each time the patients' electronic notes are
opened. These are triggered for those identified in any of
the groups:
• Group 1 patients: This CHD/Stroke/Diabetes (state
which) patient's (BP) or (serum cholesterol) level (specify
which) is out of the target range.
• Group 2 patients: This patient may be at high cardiovas-
cular risk, but values for the following risk variables were
either missing or out of date: (specify which variables).
• Group 3 patients: This patient's estimated cardiovascular
risk may be elevated, based on the most recent risk variable
values.(State assumptions made)Page 4 of 13
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ently elevated based on three consecutive values.
• Group 5 patients: This patient may have undiagnosed dia-
betes, based on a previous raised blood glucose level ≥ 11.1
mmol/L.
Search algorithm to identify those most likely to benefit from cardiovascular prevention based on recent risk variable valuesFigure 1
Search algorithm to identify those most likely to benefit from cardiovascular prevention based on recent risk variable values. 
Definitions for terms in inverted commas are given in the appendix along with justification of thresholds and search protocol.
Total population over 50 yrs 
On CHD, Stroke or Diabetes registers? 
Yes        No 
If most recent systolic BP > 150 mmHg 
(>145 if patient has diabetes)                 Less than 75 years old? 
or     
most recent diastolic BP > 90 mmHg                              No 
(>85 mmHg if patient has diabetes)     
or            
most recent cholesterol > 5.0 mmol/L     Yes                       Are all of the     
or                    last three BPs 
BP or cholesterol value not recorded in                     >160 (systolic) 
the past fifteen months                                     or >100(diastolic) 
                                           (where available) 
     
GROUP 1    Does the record                        
     contain “in date”       
            information on all the                
                   “Framingham variables”?             No
              Yes   
          
         No      Yes              GROUP 4
Inserting “assumed” values                                Estimated 10 yr CVD risk >20%
for the missing variables,                      based on most recent values? 
would the 10 year CVD risk be >20%? 
     Yes       No      Yes      No 
GROUP 2      GROUP 3 Page 5 of 13
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has no recorded blood glucose measurement in the past
three years.
Control condition
Control patients at high estimated risk will be identified
but the practice teams will not be provided with these
extra reminders, although the team will have access to all
the clinical information used to assess risk status. Control
patients will continue to receive the usual care provided
by current general practice under the nGMS contract.
Some practices have started to use alerts for CVD or Dia-
betes patients who are out of the nGMS blood pressure
and cholesterol targets since this study was conceived.
Where this is now 'usual care,' this part of the intervention
(Group 1 alerts) will not be withheld from the control
patients, but the rest of the e-Nudge (including identifica-
tion on the eight-weekly searches) will be. The standard of
care is high in the study locality [South Warwickshire Pri-
mary Care Trust, QOF data on file], providing a suitable
environment to test the e-Nudge. If the study shows a pos-
itive effect, this will demonstrate that even good care can
be improved, and it is anticipated that the tool will be
even more effective in environments where care is of a
lower standard.
Ethical approval
The trial has been developed in accordance with the Dec-
laration of Helsinki, and approved by Warwickshire Local
Research Ethics Committee (Ref: 05/Q2803/85).
Outcome analysis
The searches and alerts will continue for a period of two
years, at the end of which the data will be examined. We
will continue to collect and analyse data on the primary
and secondary outcomes of the study for a further year
after this. Outcomes will be measured using searches on
practice databases. Analysis will be undertaken on an
"Intention To Treat" basis within practices. Practices that
withdraw will have their data censored from the date of
withdrawal from the trial.
Primary outcome
Difference in the annual incidence rate of cardiovascular
events (see definition in the appendix) in the intervention
and control populations during the two years of the study,
Identification of Group 5Figure 2
Identification of Group 5.
Total population over 50 yrs 
On Diabetes register? 
No
Is there a random blood 
glucose value > 11.1mmol/L?, 
without a subsequent FBG < 6.9 
or  OGTT code 
   Yes    
               Yes            
                          No 
          GROUP 5Page 6 of 13
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intervention.
Secondary outcomes
• Difference in the proportion of high risk patients
(Groups 1, 3 and 4) identified in the control and interven-
tion populations averaged over the last three searches in
the two year intervention period, and in the third year fol-
lowing the end of the intervention.
• Difference in the proportion of patients in each popula-
tion identified with missing data (Groups 2 and 6) aver-
aged over the last three searches in the two year
intervention period, and in the third year following the
end of the intervention.
• Difference in the proportion of patients with undefined
diabetes status (i.e. raised blood glucose levels with no
diagnosis of diabetes and no FBG or OGTT results to con-
firm status) (Group 5) in the intervention and control
populations averaged over the last three searches in the
two year intervention period, and in the third year follow-
ing the end of the intervention.
Statistical analysis
Analysis of the data will be carried out in STATA. The prin-
ciple analyses will be on an intention-to-treat basis and
will be performed using the CONSORT guidelines (2001)
[34].
Data monitoring committee
Outcomes will be assessed annually during the study by
an independent data monitoring committee, who will
inform the trial investigators if the trial should terminate
early on ethical grounds due to a 20% difference in mor-
tality or morbidity between the intervention and control
groups.
Data quality assurance measures
We will examine the cause of death of every patient in the
practices over age 50 years who dies during the study, to
ensure that all cardiovascular deaths are recorded appro-
priately in searchable form prior to outcome data extrac-
tion. Any patient recorded as having more than one
cardiovascular event during the study will have their clin-
ical record examined, to identify patients who have had
the same event recorded twice (which may happen when
a consultation for a stroke, TIA or myocardial infarction is
mistakenly labelled as a "new episode" rather than a
"review"). This process will be carried out both on con-
trols and intervention patients. In addition, we will exam-
ine the notes of any patient who has a record of an event
dated within 4 months of registration with a practice, in
case this event occurred in the past but was incorrectly
dated when the patient registered.
Sample size calculation
Event rates
Our study defines a cardiovascular event as a new diagno-
sis of CVD, a new myocardial infarction, a new stroke, a
new transient ischaemic attack, or sudden death from
CVD. A new stroke in someone with a previous stroke will
Identification of Group 6Figure 3
Identification of Group 6.
Total population over 50 yrs 
On CHD or Stroke/TIA register? 
  No       Yes 
Is there a blood glucose measurement 
in the record in the past 3 years? 
Yes     No 
GROUP 6 
Eight-weekly searches on practice databasesFi ure 4
Eight-weekly searches on practice databases.
Randomisation
Control patients                     Intervention patients 
SEARCH
    High risk control       High risk intervention 
             patients        patients 
 Record made of search result 
with date, but no      Lists presented 
              further action                   to practice teams 
   Page 7 of 13
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patient previously diagnosed with angina will be recorded
as a new event, but a new onset of angina in a patient who
already had a diagnosis of acute myocardial infarction
might not be recorded as a new diagnosis, as the patient
will already be on the CHD register.
The British Heart Foundation [35] has compiled an esti-
mate of the number of cardiac events in the UK popula-
tion in 2002 from several available data sources. The
number of myocardial infarctions (all ages) was estimated
to be 268,000, while the number of new cases of angina
(all ages) was estimated to be 338,000
The UK population was 59,321,700 in 2002 [Sources:
Office for National Statistics, General Register Office for
Scotland, Northern Ireland Statistics and Research
Agency], so estimated incidence rates for coronary heart dis-
ease are
Incidence of myocardial infarction 451.77 per 100,000
Incidence of new case of angina 569.77 per 100,000
For cerebrovascular disease, the OXVASC study [36] pro-
vides a local source of information drawn from an
Oxfordshire population. The incidence rates were:
Incidence of stroke 187 per 100,000
Incidence of TIA 51 per 100,000
Therefore
Incidence of all cardiovascular events 1260 per 100,000
Clinical significance
We aim to demonstrate at least a 10% reduction in the car-
diovascular event rate. This means that for a positive out-
come, the event rate in the intervention population must
be ≤90% of the event rate in the control population. We
therefore estimated the necessary sample size for this
reduction to be detected at the 5% level with 80% power.
Estimating population size needed
A Poisson distribution model is appropriate for events
that are rare on an individual level, occurring randomly
and independently at a constant rate in a population [37].
Assuming a Poisson distribution, the formula for the sam-
ple size is:
where:
λ0 = the expected incidence of cardiovascular events (i.e.
1260/100,000)
δ = new incidence in the intervention group
z1-α = standardised normal distribution value based on
0.05 significance level
z1-β = standardised normal distribution values for 80%
power
N = total number of patients required in the study
Nw = total number of patients required in the study + 10%
to account for practice withdrawal
For 80% power and 0.05 significance level (2-tailed) [38]
(see Table 1):
The practice population required to detect both statisti-
cally and clinically significant changes in the cardiovascu-
lar event rate is therefore estimated to be approximately
70,000, the combined list size of all age groups in partici-
pating practices.
Discussion
We have described the protocol of our trial of an elec-
tronic reminder system (the e-Nudge) that aims to change
general practitioners' behaviour with respect to patients at
risk of CVD. The trial will use routinely collected elec-
tronic data to repeatedly flag up high-risk patients and
will measure the outcomes in terms of cardiovascular
event rates and the risk profile of the over-50 year popula-
tion. Electronic alert messages are now commonly used in
the increasingly integrated software environment of UK
primary care, but the evidence to support them is incon-
clusive. This trial will attempt to provide a more robust
evidence base for the use of such tools for preventive care
in UK general practice.
N
z z
=
+ +
− −
[ ( )]1 0 1 0
2
2
α βλ λ δ
δ
Table 1: 
Reduction in incidence (%) z1-α z1-β λ0 δ N Nw
10 1.96 0.8416 0.0126 0.001260 64133.46 70546.80Page 8 of 13
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project included those of data quality and software inter-
operability. Because the coding of clinical data under the
nGMS is linked to remunerative targets, a widespread
standardisation of Read coding has occurred since 2004 in
areas of care related to chronic disease management.
Without this development it is doubtful that a trial of this
design could be conducted. Despite this, the use of alter-
native codes within the nGMS contract for data such as
blood glucose values made the programming of the search
algorithm challenging, particularly as more than one hos-
pital laboratory (which generate these data for practices
through electronic links) are involved in the study area.
The identification of individual patients' smoking status
was designed with current recording practice in mind, and
this area of the program was the least secure in terms of
accuracy, as it is not always possible to determine from
electronic records exactly how long ago an ex-smoker
quitted. Participating clinicians are made aware of the
limitations of this part of the program so that adjustments
can be made based on a knowledge of the patient's actual
smoking history.
The e-Nudge Trial is an example of a new model of pri-
mary care research. It involves the flow of information out
of the databases of participating practices to the practising
teams, to then influence clinical behaviour and future
data patterns. The search techniques involved include not
only the identification of patients according to the pres-
ence in their notes of coded data, but a computation (using
in this case the Framingham CVD algorithm) to define a
more complex decision boundary between the high risk
and low risk patients in a live database. This approach has
become necessary in the light of the most recent guide-
lines on the prevention of cardiovascular disease [4],
which explicitly support the definition of the hypertensive
and hyperlipidaemic populations according to overall car-
diovascular risk, estimated using both risk algorithms and
other information known to the clinician. Such algo-
rithms might lend themselves to future adaptation, by
broadening the range of input risk variables, the use of
alternative statistical models for the classification of high
risk groups, and tailoring to regional populations [33].
The appendices describe the evidence behind the choices
made in designing the study including thresholds,
assumed values, and definitions.
Appendices
1. Justification for the thresholds and search protocols
used in the study
a) Age group
b) The high CVD risk group (Group 3)
2. Identifying patients with undiagnosed diabetes
3. Screening for type 2 diabetes in populations at risk of
CVD
4. Search groups 1, 3 and 4
5. Definitions:
a) "In date"
b) "Framingham variables"
c) "Assumed values"
d) "Cardiovascular event"
1. Justification for the thresholds and search protocols used 
in the study
a) Age group
We decided to include in the searches only those patients
over 50 yrs, as the prevalence of cardiovascular disease
begins to climb steeply at this age [35]. As the main out-
come involves a comparison of the effect of the interven-
tion on event rates, this will avoid the dilution of each
denominator population by low risk patients.
b) The high CVD risk group (Group 3)
The group at high risk of CVD (but who do not already
have CHD, Stroke/TIA, or Diabetes) is defined not by a
simple combination of diagnostic categories, but as the
output of a risk prediction algorithm. The Framingham
study data [39] is currently the best available source for
patients without CVD under 75 years, and is recom-
mended in the CHD NSF [3] and the 2004 British Hyper-
tension Society Guidelines [40], despite some concern
over its applicability to the UK population [41]. We will
be using the most recent values as inputs for this algorithm.
Whilst the recommended approach is to use values prior
to treatment with antihypertensive or lipid lowering ther-
apy, our approach is similar to that applied to individuals
in existing prediction tools [42,43] that can compare "pre-
treatment" with "post-treatment" risk, to emphasise the
impact on risk of intervention such as drug therapy and
lifestyle modification. We are therefore making no dis-
tinction between the estimated risk levels of two patients
with identical risk profiles including blood pressure, one
of whom is on antihypertensive treatment and the other is
not. In fact the treated patient, whilst having a signifi-
cantly lower cardiovascular risk than before commencing
therapy, still has a higher risk (not recognised by our
search protocol) than the otherwise similar patient with
the same blood pressure not requiring therapy. Despite
this limitation, this approach is currently the most effec-
tive means of utilising primary care data (where "pre-Page 9 of 13
(page number not for citation purposes)
Trials 2006, 7:11 http://www.trialsjournal.com/content/7/1/11treatment" blood pressure or lipid levels are often not
identifiable), and is very much in keeping with the moni-
toring process of the QOF, which measures performance
according to the most recent values of variables such as
blood pressure or serum cholesterol.
2. Identifying patients with undiagnosed diabetes
The application of these searches provides an opportunity
to identify patients who may have undiagnosed diabetes.
Such searches have been shown to include patients absent
from diabetes registers with blood glucose measurements
above the usual diagnostic threshold of 11.1 mmol/L. For
instance, the Diabetes Audit and Research in Tayside Scot-
land (DARTS) study [44] identified 701 patients with iso-
lated hyperglycaemia in a number of primary and
secondary care registers, from a population of 391 274.
This figure was 9.2% of the 7596 identified with diabetes.
Whilst such patients (particularly if asymptomatic)
require further investigation to clarify their diabetes status
[45], a number may benefit through earlier detection and
treatment if diabetes is confirmed. During pilot work in
one local practice, a search identified the following (see
Table 2):
Of these six:
1. Four patients had undiagnosed type 2 diabetes later
confirmed by fasting blood glucose measurements.
2. One patient had impaired fasting glycaemia (FBG 6.9
mmol/L) and is awaiting further investigation with OGTT
to exclude diabetes.
3. One patient had probable steroid induced hyperglycae-
mia and has had a normal blood glucose value recorded
since stopping the steroids.
We are therefore including as part of the regular searches
a query to identify such patients, who may have undiag-
nosed diabetes based on previous raised measurements.
Such patients identified in this study will need to have a
subsequent non-diabetic fasting blood glucose level (≤6.9
mmol/L) or Oral Glucose Tolerance Test in order that
future searches classify them as not having diabetes (see
also appendix 5 below). Some of these patients in whom
diabetes appears to be refuted by fasting measurements
may go on to have further abnormal plasma glucose lev-
els, in which case they will again be identified as possible
cases (Group 5) until a further normal fasting glucose
level is obtained, or a diagnosis of diabetes is made.
3. Screening for type 2 diabetes in populations at risk of 
CVD
Diabetes UK has issued a position statement on the early
identification of people with type 2 diabetes [46]. Among
other groups, this document identifies people with ischae-
mic heart disease, cerebrovascular disease, peripheral vas-
cular disease or hypertension as high risk groups justifying
screening, with a screening interval of three years. How-
ever a reliable and practical screening test has not been
established. Whilst fasting plasma glucose estimation is
significantly more specific than random plasma glucose
estimation, it is less practical. In addition to the detection
of possibly undiagnosed patients described above, we
have therefore designed the study to encourage blood glu-
cose testing at least every three years in groups who either
have, or who are at high risk of CVD. These tests can be
carried out during the routine blood checks that patients
receive for monitoring of lipid lowering or anti-hyperten-
sive therapies. Therefore negative diabetes status will only
be assumed if the patient is not on the Diabetes register
and a normal plasma glucose level (random or fasting) is
present in the record within the three years prior to the
search. We will be allowing the follow up of patients with
borderline plasma glucose levels to remain at the discre-
tion of the practices. (The recently published Joint British
Societies guidelines on prevention of cardiovascular dis-
ease in clinical practice (JBS 2), clarifies currently recom-
mended practice in this area for the first time [4].) This
study may be able to determine whether this approach is
useful as a means of detecting type 2 diabetes earlier in
these groups, given its practicality and low cost. Practices
are at liberty to use more specific screening tests on any
individual whom they feel justifies it.
4. Search groups 1, 3 and 4
The Group 1 patients are identified on the basis of thresh-
olds used as audit targets in the nGMS contract for second-
ary prevention. Whilst these treatment targets are
essentially arbitrary [47], they have been selected through
extensive discussions between the Department of Health
and expert advisory bodies. Following advice in the
National Service Framework for Diabetes [48] and sup-
ported by the 2004 BHS guidelines [40] and JBS 2 [4], the
nGMS QOF recommends that patients with diabetes are
treated as if they already have cardiovascular disease in
terms of cholesterol and blood pressure control. The latter
in fact requires tighter target levels than for patients with
CVD alone. For this reason they will similarly be regarded
as secondary prevention patients in this study.
For primary prevention (Group 3 and Group 4), the Brit-
ish Hypertension Society Guidelines (2004) recommend
Table 2: 
Currently registered patients: 12,245
Plasma glucose on record ≥ 11.1 mmol/L but no 
diagnosis of diabetes
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≥20% as a threshold for treatment of grade I hypertension
with antihypertensive drugs, or lipid lowering therapy in
all groups at this risk level up to the age of 80 yrs [40].
However, the Framingham algorithm is not designed to
be used in patients over 75 years of age, and the CHD NSF
[3] recommends that the systematic identification of new
primary prevention candidates (particularly for lipid low-
ering therapy) should stop at age 74 years. However, older
hypertensive patients benefit from blood pressure reduc-
tion and the identification of patients with grade II hyper-
tension or higher, based on serially elevated blood
pressure measurements can therefore be justified above
this age limit. Whilst it might be justifiable to reduce this
threshold (for instance to identify older patients with
grade I rather than grade II hypertension), this would
involve identifying potentially large numbers of patients
whose need for treatment was not as clear, adding consid-
erably to the workload involved.
5. Definitions
5a "In date" means:
1. A blood pressure reading within the last fifteen months
for patients who have CHD/Stroke/TIA or Diabetes, oth-
erwise three years.
2. A blood glucose level within the last three years (for
those without diabetes).
3. A cholesterol level in the last fifteen months for CHD,
Stroke/TIA or Diabetes patients, and three years for non-
CHD/Stroke/TIA, non-Diabetes patients (applies to possi-
ble Group 2 patients, see next section).
5b "Framingham variables", in this study means:
1. Age
2. Sex
3. Smoking status (considered positive if record of smok-
ing tobacco at last use of this Read code group, however
long ago). A previously recorded smoker who has stopped
will be considered a non-smoker only if 1 year has elapsed
since quitting. Therefore a "smoker" is anyone who has
smoked tobacco regularly in the past 1 year.
4. Systolic blood pressure – average of last three "in date"
values if available. If there are fewer measurements avail-
able, then the average of these is taken.
5. Total serum cholesterol at most recent measurement, if
"in date"
6. Serum HDL cholesterol – as for total cholesterol
7. Left Ventricular Hypertrophy status – assume negative
unless there is any positive electronic record of LVH.
8. Diabetes status, according to whether or not the patient
is on the Diabetes register. However, as discussed above,
this depends on the quality of such registers. If a primary
prevention patient less than 75 yrs does not have a diag-
nosis of diabetes, but there is no blood glucose level "in
date" (i.e. in the past three years), then the risk algorithm
will base the risk calculation on an assumption of positive
Diabetes status, and if the risk level is then high, the prac-
tice will be notified with this assumption stated, as a
Group 2 Alert message. If a patient (this time including
those above 75 yrs) is not on the Diabetes register but
there is a record of a blood glucose level greater than or
equal to 11.1 mmol/L, then the practices will be notified
for clarification, regardless of the patient's CHD/Stroke
status or calculated risk level as a Group 5 patient. The
matter can be clarified by the practice teams if they wish,
by organising a Fasting Blood Glucose (FBG) or Oral Glu-
cose Tolerance Test (OGTT). A FBG ≤6.9 mmol/L or OGTT
code following (at a later date to) the high random blood
glucose level will mean that the patient is no longer in
Group 5 (but may re-enter it if further raised blood glu-
cose levels occur). The FBG or OGTT must be clearly
recorded electronically by the practices using appropriate
codes (to distinguish fasting values from random blood
glucose values), or the patient will continue to be flagged
up in subsequent searches. If, despite a normal FBG result
or OGTT, a further raised random value subsequently
occurs (≥ 11.1 mmol/L) then once again the program will
question whether or not the patient has diabetes by
including them in Group 5, until a further FBG ≤ 6.9 or
OGTT code is recorded, or the patient is diagnosed and
added to the Diabetes register.
5c "Assumed values" for the missing variables means:
1. For systolic blood pressure: Male 135 mmHg, Female
132 mmHg
2. For total serum cholesterol: Male 5.7 mmol/L, Female
6.2 mmol/L
3. For HDL cholesterol: Male 1.4 mmol/L, Female 1.7
mmol/L
4. For diabetes: positive status.
5. For smoking status: non-smoker.
These blood pressure and cholesterol thresholds are the
approximate median or mean values in the 50–74 yearPage 11 of 13
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[49].
5d A "cardiovascular event" is defined as:
1. A new diagnosis of cardiovascular disease (i.e. entry
onto the CHD or Stroke/TIA registers)
2. A new stroke or transient ischaemic attack (TIA)
(whether or not already on the Stroke register)
3. A new myocardial infarction (whether or not already on
the CHD register).
4. Sudden death from cardiovascular disease.
Abbreviations
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